Rimas J Orentas

List of Publications by Year
in descending order

27 papers	5,057 citations	430874 18 h-index	610901 24 g-index
27 all docs	27 docs citations	27 times ranked	6365 citing authors

#	Article	IF	Citations
1	Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line. Frontiers in Immunology, 2022, 13, 825364.	4.8	6
2	Trispecific CD19-CD20-CD22â€"targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine, 2021, 13, .	12.4	77
3	Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nature Medicine, 2021, 27, 1544-1552.	30.7	138
4	Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma. Frontiers in Immunology, 2021, 12, 668307.	4.8	4
5	Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. Molecular Therapy, 2021, 29, 2691-2706.	8.2	18
6	T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice. , 2021, , 199-218.		0
7	Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas. , 2020, , 137-163.		2
8	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology, 2020, 158, 2250-2265.e20.	1.3	97
9	CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity. Blood, 2020, 136, 30-31.	1.4	6
10	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research, 2019, 25, 2560-2574.	7.0	369
11	CD19 CAR T cell product and disease attributes predict leukemia remission durability. Journal of Clinical Investigation, 2019, 129, 2123-2132.	8.2	244
12	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 539.	2.8	32
13	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	30.7	1,030
14	A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. , 2017, 5, 42.		196
15	Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Molecular Therapy, 2017, 25, 2189-2201.	8.2	264
16	Paired Expression Analysis of Tumor Cell Surface Antigens. Frontiers in Oncology, 2017, 7, 173.	2.8	16
17	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunology Research, 2016, 4, 869-880.	3.4	258
18	Eradication of B-ALL using chimeric antigen receptorâ€"expressing T cells targeting the TSLPR oncoprotein. Blood, 2015, 126, 629-639.	1.4	110

#	Article	IF	Citations
19	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine, 2015, 21, 581-590.	30.7	1,304
20	Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison. Frontiers in Oncology, 2014, 4, 134.	2.8	13
21	Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood, 2013, 122, 1105-1113.	1.4	144
22	Anti-CD22â€"chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 2013, 121, 1165-1174.	1.4	478
23	Lessons learned from a highly-active CD22-specific chimeric antigen receptor. OncoImmunology, 2013, 2, e23621.	4.6	25
24	Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers. Frontiers in Oncology, 2012, 2, 194.	2.8	81
25	Transduction of Primary Lymphocytes with Epstein-Barr Virus (EBV) Latent Membrane Protein-Specific T-Cell Receptor Induces Lysis of Virus-Infected Cells: A Novel Strategy for the Treatment of Hodgkin's Disease and Nasopharyngeal Carcinoma. Journal of Clinical Immunology, 2006, 26, 22-32.	3.8	27
26	Retroviral Transduction of a T Cell Receptor Specific for an Epsteinâ€"Barr Virus-Encoded Peptide. Clinical Immunology, 2001, 98, 220-228.	3.2	87
27	Feasibility of Cellular Adoptive Immunotherapy for Epstein-Barr Virus-Associated Lymphomas Using Haploidentical Donors. Stem Cells and Development, 1998, 7, 257-261.	1.0	31